Insulet (PODD) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.76% |
| Dec 31, 2025 | 19.09% |
| Sep 30, 2025 | -16.92% |
| Jun 30, 2025 | -15.99% |
| Mar 31, 2025 | 7.93% |
| Dec 31, 2024 | -18.98% |
| Sep 30, 2024 | 29.97% |
| Jun 30, 2024 | 33.99% |
| Mar 31, 2024 | 11.72% |
| Dec 31, 2023 | -124.37% |
| Sep 30, 2023 | 17.72% |
| Jun 30, 2023 | -25.89% |
| Mar 31, 2023 | -9.71% |
| Dec 31, 2022 | -37.39% |
| Sep 30, 2022 | -20.37% |
| Jun 30, 2022 | -19.59% |
| Mar 31, 2022 | -34.48% |
| Dec 31, 2021 | -91.59% |
| Sep 30, 2021 | 15.47% |
| Jun 30, 2021 | 77.74% |
| Mar 31, 2021 | 5.35% |
| Dec 31, 2020 | -68.76% |
| Sep 30, 2020 | 60.03% |
| Jun 30, 2020 | 179.25% |
| Mar 31, 2020 | 14.09% |
| Dec 31, 2019 | 125.49% |
| Sep 30, 2019 | 18.30% |
| Jun 30, 2019 | -36.30% |
| Mar 31, 2019 | 42.56% |
| Dec 31, 2018 | -24.40% |
| Sep 30, 2018 | -113.42% |
| Jun 30, 2018 | 112.36% |
| Mar 31, 2018 | 74.91% |
| Dec 31, 2017 | 66.11% |
| Sep 30, 2017 | 13.29% |
| Jun 30, 2017 | 39.33% |
| Mar 31, 2017 | 72.14% |
| Dec 31, 2016 | 5.04% |
| Sep 30, 2016 | 32.33% |
| Jun 30, 2016 | 0.61% |
| Mar 31, 2016 | 1.75% |
| Dec 31, 2015 | 3.60% |
| Sep 30, 2015 | 8.93% |